Precision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/ AYA Malignancy‐Specific Panel Sequencing
Cancer Science · 2025
DOI: 10.1111/cas.70312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Masato Kojima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Precision oncology, based on the genomic profile of tumors, is increasing in cancer treatment. It is important in pediatric and adolescent and young adult (AYA) malignancies, a group of rare cancers that are difficult to diagnose and progress quickly. We evaluated the usefulness of in‐hospital molecular profiling using a specific sequencing panel for pediatric and AYA malignancies in clarifying the diagnosis, predicting the prognosis, and identifying therapeutic targets. We evaluated the Oncomine Childhood Cancer Research Assay (203 genes, 1700 fusions) and analyzed 153 samples at diagnosis and 34 samples at relapse or refractory from 165 pediatric and AYA patients with various solid malignancies, including neuroblastoma, hepatoblastoma, brain tumor, and sarcoma. We simulated in‐hospital molecular profiling. In total, 320 reportable variants were identified in 153 samples (81.8%). Variants with clinical significance were identified in 62 samples (33.1%), including diagnostic variants in 26 (13.9%), prognostic variants in 17 (9%), targetable variants in 41 (21.9%), and variants with drug resistance in 18 (9.6%). Additionally, 62.0% and 94.1% of identified diagnostic and prognostic variants, respectively, had high levels of evidence. In five patients with cancer predisposition syndromes, all pathogenic germline mutations were validated. The turnaround time (TAT) from sample collection to reporting of the molecular profile was within seven working days. In‐hospital molecular profiling using a sequencing panel specified tailored for pediatric and AYA malignancies has a high rate of identifying reportable variants and enables accurate diagnosis, malignancy grading, and treatment selection, as well as cancer predisposition syndromes with a short TAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Biomedical Science, Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Masato Kojima, Sho Kurihara, Isamu Saeki, Ryo Touge, Shuhei Karakawa, Fumiyuki Yamasaki, Satoshi Okada, Eiso Hiyama
Förderung
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Kojima, M., Kurihara, S., Saeki, I., Touge, R., Nakashima, K., Karakawa, S., Yamasaki, F., Okada, S., & Hiyama, E. (2025). Precision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/ AYA Malignancy‐Specific Panel Sequencing. Cancer Science. https://doi.org/10.1111/cas.70312
Vancouver
Kojima M, Kurihara S, Saeki I, Touge R, Nakashima K, Karakawa S, et al. Precision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/ AYA Malignancy‐Specific Panel Sequencing. Cancer Science. 2025. doi:10.1111/cas.70312
BibTeX
@article{Kojima2025,
author = {Kojima, Masato and Kurihara, Sho and Saeki, Isamu and Touge, Ryo and Nakashima, Keigo and Karakawa, Shuhei and Yamasaki, Fumiyuki and Okada, Satoshi and Hiyama, Eiso},
title = {Precision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/ AYA Malignancy‐Specific Panel Sequencing},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70312}
}
EUVIMED